Recent Updates
Recently added Catalysts

Bazedoxifene/conjugated estrogens combination

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Dec 28, 2007

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedUNCONTROLLED
Total Trials2
Total Enrollment52
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00550303Study Comparing Formulations of Bazedoxifene/Conjugated EstrogensPHASE1 COMPLETED 28Oct 1, 2007Nov 1, 2007Dec 27, 2007 -
NCT00465075Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations in Fed and Fasting in Healthy, Postmenopausal WomenPHASE1 COMPLETED 24Mar 1, 2007Apr 1, 2007Dec 28, 20071 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Bioavailability
PK parameters
Secondary Endpoints
Safety & tolerability
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeTREATMENT
Interventions
NameTypeDescription
bazedoxifene/conjugated estrogens combinationDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range45 Years — 70 Years
SexFEMALE
Healthy VolunteersYes

Inclusion Criteria: * Healthy, post menopausal women ages 45 to 70 Exclusion Criteria: * Male subjects

Countries:United States
Unlock Eligibility Criteria